Remarkable 99mTc-FAPI-46 Uptake in a Patient With Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40065418.
- Also identified by DOI 10.1097/RLU.0000000000005746.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fibroblast activation protein (FAP)-targeted radionuclides are known as a promising step in cancer diagnosis and treatment (theranostic), although it is still a subject under investigation. We present a patient with anaplastic thyroid carcinoma who underwent 99mTc-FAPI-46 SPECT/CT for the evaluation of metastatic disease. Several metastatic sites were found with considerable 99mTc-FAPI-46 uptake. Malignant FAPI uptake was observed in the large calcified thyroid mass, mediastinal lymph node, both lungs, liver, few skeletal sites, and around knees prostheses. Given the notable uptake of lesions, the patient was considered as a candidate for FAP-targeted radionuclide therapy.
Medical subject headings
- Organotechnetium Compounds
- Thyroid Carcinoma, Anaplastic
- Thyroid Neoplasms